Physician review
Prescription decisions begin with medical-history and contraindication review by Dr. Anjmun Sharma, MD.
✓ Medically reviewed by Dr. Anjmun Sharma, M.D., Updated May 2026
An Ozempic Alternative That Won't Break the Bank
The dispensing pharmacy label identifies the compounded preparation as semaglutide. It is a different product from FDA-approved brands, is not FDA-approved or brand-identical, and results vary.
ozempic alternativeozempic cliniccheaper than ozempicozempic without insurancealternatives to ozempic
Quick answer
The dispensing pharmacy label identifies the compounded preparation as semaglutide. It is a different product from FDA-approved brands, is not FDA-approved or brand-identical, and results vary. New Hope Weight Loss is not affiliated with Novo Nordisk or the Ozempic brand; we offer cash-pay compounded semaglutide from $166 per month with no insurance required and a $119 telehealth consultation to start.
Important: Compounded semaglutide and tirzepatide are not FDA-approved and are not brand-identical. Eligibility and results vary.
Costs less than your daily coffee.
A daily latte~$6/day
Your weight-loss plan$5.50/day$39/week
$166 a month, physician-supervised, no insurance needed.
Why People Look for an Ozempic Alternative
Ozempic® is a registered trademark of Novo Nordisk A/S and is approved by the FDA for specific uses. But for many people it's hard to get: list prices can exceed $1,000/month without insurance, coverage is inconsistent, and the 2024-2025 shortages showed how unreliable access can be. That's why so many search for a more accessible alternative.
New Hope Weight Loss is not affiliated with Novo Nordisk A/S. The dispensing pharmacy label identifies the compounded preparation as semaglutide. It is a different product from FDA-approved brands, is not FDA-approved or brand-identical, and results vary.
How the Compounded Option Compares
| Brand-name Ozempic | Compounded Semaglutide at NHWL | |
|---|---|---|
| Active ingredient | Semaglutide | Label identifies semaglutide; separate compounded product |
| Typical monthly cost | $1,000+ (no insurance) | from $166/mo |
| Physician supervision | Varies | Always, Dr. Sharma |
| FDA-approved product | Yes | No (compounded) |
| Insurance required | Often | Never |
Compounded medications are not FDA-approved products, are not brand-identical, and results vary. Any prescription requires individualized medical review and lawful pharmacy fulfillment. Dr. Sharma will tell you honestly whether you're a good candidate.
What You Pay at New Hope Weight Loss
- $119 one-time, Dr. Sharma's review + first prescription.
- $499 for a 3-month plan = $166/month.
- $199 one-month trial to start small.
HSA/FSA accepted. Klarna and Affirm financing available. No insurance, ever.
Estimate Your Savings
Frequently asked questions
Is there a cheaper alternative to Ozempic?
The dispensing pharmacy label identifies the compounded preparation as semaglutide. It is a different product from FDA-approved brands, is not FDA-approved or brand-identical, and results vary. Compounded medications are not FDA-approved and are not identical to the brand, but they are a legal, supervised, more accessible option.
Can I get Ozempic without insurance?
Brand-name Ozempic typically requires insurance or out-of-pocket payment exceeding $1,000/month. New Hope Weight Loss never requires insurance, compounded semaglutide is cash-pay from $166/month with HSA/FSA accepted.
Is the compounded version the same as Ozempic?
The dispensing pharmacy label identifies the compounded preparation as semaglutide. It is a different product from FDA-approved brand products, is not FDA-approved or brand-identical, and results vary. Any prescription requires Dr. Sharma's review and depends on lawful pharmacy fulfillment for the patient's location.
How do I switch from Ozempic to the compounded option?
Take our 2-minute quiz and complete the medical intake form. Tell Dr. Sharma about your current dose and history; she'll determine the right starting plan and supervise the transition.
Transparent pricing
$166/month
About $5.50 a day, less than a daily latte
A fraction of brand-name GLP-1 list prices, which often run $900 to $1,300 or more a month.
- Licensed U.S. physician, supervised the whole way
- Compounded semaglutide included
- Only if a prescription is approved and the dispensing pharmacy can fulfill it for your location, the pharmacy confirms packaging and shipping details before fulfillment
- Ongoing dose adjustments and support
- No insurance needed, HSA and FSA plus financing accepted
$119 one-time to get started with your physician consultation.
Medical disclaimer: Individual results may vary. GLP-1 medications require a physician prescription and ongoing supervision. Clinical trial results cited are averages; not all patients achieve the same outcomes. Eligibility is determined during the medical consultation. This information does not replace professional medical advice.
New Hope Weight Loss | 1503 South Coast Drive, Suite 322, Costa Mesa, CA 92626 | (657) 837-3342
Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. Compounded semaglutide and tirzepatide are not FDA-approved or brand-identical and have not undergone FDA premarket review for safety, effectiveness, or quality. Results vary. Any prescription depends on individualized medical review and lawful pharmacy fulfillment for the patient's location.
What Ozempic Is Actually Approved to Treat
Ozempic is the Novo Nordisk brand of semaglutide, and its FDA labeling covers three uses that are all tied to type 2 diabetes. The first is improving blood sugar control in adults with type 2 diabetes, alongside diet and exercise. The second is reducing the risk of major adverse cardiovascular events in adults who have both type 2 diabetes and established cardiovascular disease. The third, added by the FDA in January 2025, is reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. That kidney indication is carried by no other semaglutide or tirzepatide brand.
What the Ozempic label does not include is chronic weight management. Weight change reported in its diabetes trials was a secondary observation, not the approved purpose. Novo Nordisk has a separate semaglutide product, Wegovy, that carries the weight-management labeling, and Ozempic labeling is limited to adults while Wegovy injection labeling reaches adolescents 12 and older. Semaglutide is a GLP-1 receptor agonist, acting on one incretin receptor; tirzepatide, the molecule behind Mounjaro and Zepbound, acts on two.
None of this describes a compounded preparation. Compounded semaglutide is not FDA-approved, is not brand-identical, has not gone through FDA premarket review for safety, effectiveness, or quality, and results vary. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S, and New Hope Weight Loss is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Dr. Sharma reviews your history, including kidney and cardiac history, before any prescribing decision.
Ozempic is approved for diabetes. I do not have diabetes. Does that matter?
It matters for how you read the label. Every FDA-approved use of Ozempic requires type 2 diabetes: blood sugar control, cardiovascular risk reduction in adults who also have established cardiovascular disease, and kidney risk reduction in adults who also have chronic kidney disease. Chronic weight management is not on that label at all. Whether a compounded semaglutide preparation is appropriate for you is a separate clinical question that Dr. Sharma answers during your consultation.
Does the Ozempic kidney indication apply to a compounded preparation?
No. That indication belongs to the FDA-approved Ozempic product from Novo Nordisk, and it rests on trials of that specific product in adults who had both type 2 diabetes and chronic kidney disease. A compounded preparation is a different product that has not gone through FDA premarket review, so brand findings cannot be assumed to carry over to it. Tell Dr. Sharma about any kidney condition during your intake.
Is Ozempic a weight loss drug?
Not according to its FDA labeling. Ozempic is approved for blood sugar control in adults with type 2 diabetes and for cardiovascular and kidney risk reduction within specific diabetes populations. Weight reduction seen in those diabetes trials was a secondary finding rather than an approved use, and Novo Nordisk markets a separate semaglutide product for chronic weight management. What is prescribed here, when appropriate, is a compounded preparation, not a brand product, and it is not FDA-approved.